A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.
复制标题
DOI:
10.1016/j.eururo.2019.09.006
复制
发表时间:
2020-04
期刊:
影响因子:
23.4
通讯作者:
Bladder Cancer Molecular Taxonomy Group
中科院分区:
文献类型:
--
作者:
Kamoun A;de Reyniès A;Allory Y;Sjödahl G;Robertson AG;Seiler R;Hoadley KA;Groeneveld CS;Al-Ahmadie H;Choi W;Castro MAA;Fontugne J;Eriksson P;Mo Q;Kardos J;Zlotta A;Hartmann A;Dinney CP;Bellmunt J;Powles T;Malats N;Chan KS;Kim WY;McConkey DJ;Black PC;Dyrskjøt L;Höglund M;Lerner SP;Real FX;Radvanyi F;Bladder Cancer Molecular Taxonomy Group
Muscle-invasive bladder cancer (MIBC) is a molecularly diverse disease with heterogeneous clinical outcomes. Several molecular classifications have been proposed, but the diversity of their subtype sets impedes their clinical application. To achieve an international consensus on MIBC molecular subtypes that reconciles the published classification schemes. We used 1750 MIBC transcriptomic profiles from 16 published datasets and two additional cohorts. We performed a network-based analysis of six independent MIBC classification systems to identify a consensus set of molecular classes. Association with survival was assessed using multivariable Cox models. We report the results of an international effort to reach a consensus on MIBC molecular subtypes. We identified a consensus set of six molecular classes: luminal papillary (24%), luminal nonspecified (8%), luminal unstable (15%), stroma-rich (15%), basal/squamous (35%), and neuroendocrine-like (3%). These consensus classes differ regarding underlying oncogenic mechanisms, infiltration by immune and stromal cells, and histological and clinical characteristics, including outcomes. We provide a single-sample classifier that assigns a consensus class label to a tumor sample’s transcriptome. Limitations of the work are retrospective clinical data collection and a lack of complete information regarding patient treatment. This consensus system offers a robust framework that will enable testing and validation of predictive biomarkers in future prospective clinical trials. Bladder cancers are heterogeneous at the molecular level, and scientists have proposed several classifications into sets of molecular classes. While these classifications may be useful to stratify patients for prognosis or response to treatment, a consensus classification would facilitate the clinical use of molecular classes. Conducted by multidisciplinary expert teams in the field, this study proposes such a consensus and provides a tool for applying the consensus classification in the clinical setting.
登录
查看更多内容
影响因子:
4.6
作者:
Aine M;Eriksson P;Liedberg F;Sjödahl G;Höglund M
通讯作者:
Höglund M
影响因子:
28.2
作者:
Pal SK;Rosenberg JE;Hoffman-Censits JH;Berger R;Quinn DI;Galsky MD;Wolf J;Dittrich C;Keam B;Delord JP;Schellens JHM;Gravis G;Medioni J;Maroto P;Sriuranpong V;Charoentum C;Burris HA;Grünwald V;Petrylak D;Vaishampayan U;Gez E;De Giorgi U;Lee JL;Voortman J;Gupta S;Sharma S;Mortazavi A;Vaughn DJ;Isaacs R;Parker K;Chen X;Yu K;Porter D;Graus Porta D;Bajorin DF
通讯作者:
Bajorin DF
影响因子:
10.3
作者:
Mo, Qianxing;Nikolos, Fotis;Chan, Keith Syson
通讯作者:
Chan, Keith Syson
影响因子:
2
作者:
Horsman MR;Overgaard J
通讯作者:
Overgaard J
DOI:
10.3233/blc-150037
发表时间:
2016-01-07
期刊:
Bladder cancer (Amsterdam, Netherlands)
影响因子:
--
作者:
Lerner SP;McConkey DJ;Hoadley KA;Chan KS;Kim WY;Radvanyi F;Höglund M;Real FX
通讯作者:
Real FX